Table 7.
Impact of Achieved BP on First Stroke in Multivariate‐Adjusted Models Including Concomitant Other Antihypertensive Drugs During the Treatment Period
| Variables | Outcome, No. (%) | Adjusteda HR (95% CI) |
|---|---|---|
| Proportion of visits with BP <140/90 mm Hg | ||
| <25% | 11 (3.7) | Ref |
| 25% to <50% | 13 (1.8) | 0.46 (0.21–1.04) |
| 50% to <75% | 16 (1.3) | 0.32 (0.15–0.70) |
| ≥75% | 12 (1.3) | 0.34 (0.14–0.80) |
| P for trend | 0.015 | |
| Time‐averaged SBP, mm Hg | ||
| <120 | 3 (2.9) | 3.48 (1.00–12.06) |
| 120 to <140 | 24 (1.1) | Ref |
| ≥140 | 25 (2.9) | 2.63 (1.47–4.73) |
| Time‐averaged DBP, mm Hg | ||
| ≥90 | 7 (2.7) | Ref |
| <90 | 45 (1.5) | 0.40 (0.17–0.98) |
| 80 to <90 | 23 (1.5) | 0.46 (0.14–1.50) |
| 75 to <80 | 10 (1.2) | 0.28 (0.09–0.83) |
| <75 | 12 (2.2) | 0.44 (0.18–1.09) |
BP indicates blood pressure; DBP, diastolic blood pressure; HR, hazard ratio; SBP, systolic blood pressure.
a
Adjusted for age, sex, study centers, methylenetetrahydrofolate reductase C677T polymorphism, study treatment groups, body mass index, smoking, alcohol drinking, systolic and diastolic blood pressure, estimated glomerular filtration rate, fasting glucose, total cholesterol, folate, vitamin B12, and homocysteine levels at baseline, as well as concomitant use of calcium channel blockers and diuretics during the treatment period.